A Phase 3, Open-Label, Multicenter Study of a 6-Month Pre-Mixed Depot Formulation of Leuprolide Mesylate in Advanced Prostate Cancer Patients

World Journal of Urology - Germany
doi 10.1007/s00345-019-02741-7

Related search